Cisplatin Platinol, Platinol-AQ
Used in colorectal cancer outside its approved indication. It appears in 43 clinical trials.
What it is
Cisplatin is a platinum-based chemotherapy agent used in colorectal cancer primarily for peritoneal carcinomatosis through pressurized intraperitoneal aerosol chemotherapy (PIPAC) and in combination regimens for advanced metastatic disease. While not part of standard first-line CRC treatment protocols, it serves as an alternative cytotoxic agent in refractory cases or specific delivery methods like intraperitoneal administration. The drug is typically reserved for patients who have progressed on standard fluoropyrimidine-based regimens or in specialized treatment approaches for peritoneal metastases.
How it works
Cisplatin forms DNA cross-links by binding to purine bases, particularly guanine, creating both intrastrand and interstrand DNA crosslinks that prevent DNA replication and transcription. These platinum-DNA adducts trigger apoptotic pathways and cell cycle arrest, particularly affecting rapidly dividing cancer cells. The drug's cytotoxicity is enhanced in hypoxic tumor environments and works synergistically with other DNA-damaging agents.
Common side effects
Not all are listed, and everyone experiences them differently. If you notice any, tell your care team.
Trials with this drug
13 recruitingGuides that may help
Written for patients and families, in plain language.